Day: October 20, 2025

Trondheim, 20 October 2025 NORBIT today announces that segment PIR has received a new contract manufacturing order, valued at approximately NOK 120 million from an undisclosed European client in the defence and security sector. Deliveries under the order are scheduled for late 2025 and early 2026. The contract follows another recently received award of approximately NOK 100 million for initial deliveries early first quarter 2026. “We are proud to see that our strategic partnerships in this domain continue to evolve. In today’s complex geopolitical landscape, the strong momentum in the defence and security industry endures. As an industrial scaling partner, we have taken the necessary steps to build capacity and inventory through close collaboration with our clients, ensuring preparedness to deliver as opportunities mature. Positioning...

Aspocomp Group Plc, Investor News, October 20, 2025, at 10:00 a.m. Finnish time Aspocomp will publish its January-September Interim Report 2025 on Thursday, October 30, 2025, at around 9:00 a.m. Finnish time. Aspocomp’s CEO Manu Skyttä will present January-September Interim Report 2025 in a webcast on the same day starting at 1:00 p.m. Finnish time. The webcast will be held in Finnish and can be accessed at https://aspocomp.events.inderes.com/q3-2025. Questions are requested to be submitted in writing via the chat functionality of the webcast portal. The presentation material in English, and a recording of the webcast (in Finnish) will be available at Aspocomp’s. For further information, please contact Manu Skyttä, President and CEO,tel. +358 20 775 6860, manu.skytta(at)aspocomp.com. Aspocomp – heart of your technology A printed circuit...

Antwerp, Oct. 20, 2025 (GLOBE NEWSWIRE) — CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) has mandated Danske Bank, DNB Carnegie, Nordea Bank and Pareto Securities to arrange a series of fixed income investor meetings commencing today, October 20, 2025.   Following the investor meetings a USD denominated five-year senior unsecured bond issue may follow, subject to inter alia market conditions. The proceeds from the potential bond issue will be used for general corporate purposes of the Group including refinancing of existing debt.  For additional information please contact our head of Investor Relations Joris Daman – joris.daman@cmb.tech  About CMB.TECH CMB.TECH is one of the largest listed, diversified and future-proof maritime groups in the world with a fleet of about 250 vessels:...

Antwerp, Oct. 20, 2025 (GLOBE NEWSWIRE) — CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) provides a market update. During Q3 and Q4 to date, CMB.TECH has continued its fleet rejuvenation strategy with the sale of two older vessels and the delivery of five newbuild vessels.   Fleet update  Deliveries  CMB.TECH took delivery of 5 newbuilding vessels in Q3 and Q4 to date:  Eco-Newcastlemaxes: Mineral Slovensko and Mineral Slovenija Chemical tanker: Bochem Santos CTV: Windcat 58 CSOV: Windcat Rotterdam Sales & TC updates  Euronav   CMB.TECH has sold the VLCC Dalma (2007, 306,543 dwt). The sale will generate a capital gain of 26.7 million USD. The vessel will be delivered to its new owner during Q4 2025.   The time charter of the VLCC Donoussa (2016, 299,999...

  ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumorsNew AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancers Phase 2 study met all primary efficacy endpoints and was presented across two oral presentations at the 2025 ESMO Congress in Berlin, GermanyParis, October 20, 2025. New data from the ALPHAMEDIX-02 phase 2 study (clinical study identifier: NCT05153772) evaluating AlphaMedix (212Pb-DOTAMTATE), an investigational somatostatin receptor (SSTR) targeted alpha therapy (TAT) using the lead-212...

ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumorsNew AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETs First phase 2 study to evaluate TAT with lead-212 supporting its potential to address high unmet medical needs in difficult-to-treat, rare cancers Phase 2 study met all primary efficacy endpoints and was presented across two oral presentations at the 2025 ESMO Congress in Berlin, GermanyParis, October 20, 2025. New data from the ALPHAMEDIX-02 phase 2 study (clinical study identifier: NCT05153772) evaluating AlphaMedix (212Pb-DOTAMTATE), an investigational somatostatin receptor (SSTR) targeted alpha therapy (TAT) using the lead-212 isotope,...

This announcement contains information on transactions of the acquisition of own shares of AB Artea bankas (the Bank) carried during the period specified below under the Bank’s own share buy-back programme announced on 01 October 2025.  The period during which the acquisition of the Bank’s own shares under the programme was carried out – 06.10.2025 – 17.10.2025.  Period covered by this periodic report – 13.10.2025 – 17.10.2025.  Other information: Transaction overview Date  Total number of shares purchased on the day ( units)  Weighted average price (EUR)  Total value of transactions (EUR) 2025.10.13 78,000 0.833 64,972.002025.10.14 78,000 0.831 64,818.002025.10.15 78,000 0.828 64,622.012025.10.16 78,000 0.833 65,004.002025.10.17 78,000 0.834 65,024.00Total acquired during the current week  390,000 0.832 324,440.01Total...

Mothercare plcPension contributions deferral Mothercare plc (“Mothercare”, “the Company” or “the Group”), the highly trusted British heritage brand, that connects with the parents of newborn babies and children across multiple product categories throughout their early life as parents, today announces the outcome of the request to the Trustee to further defer pension contributions. In our full year 2025 results announcement we noted that the Group’s Pension Trustee had agreed to defer the first six months’ payments of pension contributions due in the year to March 2026 and that we had requested a further deferral of such payments for the remainder of this financial year to support the Company’s cash flows whilst we are exploring growth opportunities. We are pleased to announce that the Trustee has agreed...

Aktsiaselts Infortar decided, based on the authorisation granted by the General Meeting of Shareholders held on 6 June 2025 to start the buy-back of 250,000 own shares to fulfil the conditions of the option plan. According to the resolution of the General Meeting of Shareholders the shares buy-back will take place within 5 years period. The acquisition price per share must not exceed the maximum price shall not exceed the average stock exchange price of the share of Aktsiaselts Infortar of the last 30 trading days preceding the relevant buy-back transaction by more than fifty percent (50%). The programme is managed by SEB Pank AS, which will buy back shares on behalf of Aktsiaselts Infortar. SEB Pank carries out the buyback according to the regulations and within the framework of the programme, and will make its trading decisions independently...

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 2,199,226 612.19 1,346,336,18013 October 2025 17,000 741.60 12,607,12714 October...